Smell Loss Therapy Research & Innovation at Cyrano Therapeutics

We are pioneering therapies like CYR‑064 to help patients regain their sense of smell and taste. Learn about our mission, scientific breakthroughs, and impact.

Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop a therapy for people struggling with the loss of smell and flavor.

Our mission is to push the boundaries of medical science, bringing hope and healing to patients suffering from anosmia through advanced and effective smell loss therapy & treatments. With a team of world-class researchers and clinicians, Cyrano Therapeutics is at the forefront of smell loss therapy research and development, committed to delivering breakthroughs that matter.

We understand the profound impact that smell loss can have on quality of life. That’s why our dedicated research team is focused on creating therapies that restore this essential sense. By combining cutting-edge technology with compassionate care, we aim to offer patients a pathway to recovery and a renewed sense of smell.

At Cyrano Therapeutics, we believe in the power of science to change lives. Our ongoing commitment to innovation ensures that we remain leaders in the field of smell loss therapy, constantly seeking new ways to enhance patient outcomes and improve overall well-being.

Leadership Team

Gerry Brunk

Managing Director, Lumira Ventures
& Board Member

Gerry Brunk is a cofounder and Managing Director at Lumira Ventures, a North American healthcare venture capital firm. Prior to beginning his investing career in 2002, Mr Brunk founded and served in a variety of management and board capacities at several venture capital-funded healthcare companies. Previously, he was an engagement manager in the healthcare practice of The Boston Consulting Group and a member of the investment banking group of Credit Suisse First Boston.

investor - smell loss Cyrano investor - Taka

Taka Koda

Partner, Remiges Ventures &
Board Member

Taka Koda is Partner at Remiges Ventures, a US-Japan venture capital firm focusing on therapeutics. With over 20 years of business development and venture investment experience, he founded and served in board capacities and management roles for start-up companies as well as providing advisory services for business groups. Previously, he was a member of Mitsui’s Private Equity group for venture investments and fund operations both in the US and Japan.